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Discussion: Contemporary guidelines on implantable cardioverter defibrillator (ICD)
therapy do not specifically address recommendations for secondary prevention after
life-threatening ventricular arrhythmias due to vasospasm. The arrhythmic risk of
coronary vasospasm is variable, ranging from 2% to 17%. Risk stratification is impor-
tant to effectively identify high-risk patients who may benefit from ICD implantation.
A risk prediction score has been developed by the Japanese Coronary Spasm
Association (JCSA) that includes: out of hospital cardiac arrest (4 points), smoking
history, documented angina, significant coronary stenosis, or multi-vessel spasm (2
points each), ST-segment elevation or spasm while on beta blocker therapy (1 point
each). Patients who score !6 are at the highest risk, with a predicted risk of major
adverse cardiac events of 13%. However, this score was developed and validated in
an East Asian population and there is no proof for its applicability to other ethnic-
ities. In this case, the risk of malignant arrhythmia recurrence was considered to be
low (2) according to the JCSA risk score and a reversible cause for the arrhythmia
was identified and effectively treated making very low the probability of recurrence.
Therefore, an implantable cardioverter defibrillator was not implanted. This clinical
case highlights the importance of identifying the cause of an arrhythmic episode in
order to introduce an effective therapy. Moreover, it underlines the importance of
properly stratifying the arrhythmic risk before considering the implantation of an
implantable cardioverter defibrillatoarg.
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Introduction: Atrial fibrillation (AF) is the most frequent sustained arrhythmia found
in clinical practice. Despite the association of AF with thromboembolic (TE) events,
and with dementia, the use of oral anticoagulant therapy (OAC) is still unsatisfactory.
Non-Vitamin K oral anticoagulants (NOACs) could allow a wider use of OAC. The aim
of this study was to compare the clinical characteristics of NVAF patients taking
NOACs or Vitamin K antagonists (VKA) in Italy and in the other Western Europe
Countries (OWE).
Methods: The Global Registry on Long-Term Antithrombotic Treatment in Patients
with Atrial Fibrillation (GLORIA-AF) Registry Program is a large, global, prospective
study, involving newly diagnosed AF patients with >1 stroke risk factors. The registry
consists of three overlapping phases. Present analysis refer to the baseline character-
istics in GLORIA-AF Phase III, including all eligible patients, independently of the pre-
scribed OAC. Patients were also stratified into two age-groups (<75 and >75 years).
Comparisons of baseline characteristics and antithrombotic therapy between Italy
and OWE were based on standardized differences (SD; unbalanced distributions for
values >0.10).
Results: Between 2014 and 2016, 9135 (43.0%) patients out of 21, 248 in Phase III were
enrolled from Western European countries. Italian and OWE subjects were 1378 and
7757, respectively. Patients in the age group of >75years were 47.8% (N" 659) and
44.8% (N" 3473) for Italy and OWE, respectively. No differences in age, gender and TE
risk were noticed by area of origin both in the younger (Italy—age: 656 8years; men:
61.5%; CHA2DS2-VASc score: 2.461.2 / OWE—age: 656 7years; men: 61.5%; CHA2DS2-
VASc score: 2.561.2) and in the older (Italy—age: 816 5years; men: 45.8%; CHA2DS2-
VASc score: 4.261.2 / OWE—age: 8165 years; men: 48.1%; CHA2DS2-VASc score:
4.361.3) group. In the whole population, OAC was less adopted in Italy compared to
OWE (84.0 vs. 90.6%, SD"-0.20). Regarding the <75years group, OAC was prescribed
less frequently in Italian than in OWE patients (80.4 vs. 90.2%; SD"-0.28). This was
especially true for NOACs (49.8 vs. 67.6%; SD"-0.37). Also the use of antiplatelet ther-
apy (9.0 vs. 4.6%) and the lack of any anti-thrombotic drug (10.6 vs. 5.2%) were more
common in the younger Italian subjects. In the >75years population, no differences
existed between Italy and OWE in the prescription of oral anticoagulants (87.9 vs.
91.1%) and, especially, of NOACs (60.5 vs. 63.5%). The proportion of those taking anti-
platelets did not differ between older Italian and OWE (6.4 vs. 4.9%) subjects; the
same was true for those not receiving any drug (5.8 vs. 4.0%). On the whole, lower dos-
ages of NOACs were more frequently found in Italian patients as compared to OWE
patients, particularly in those treated with rivaroxaban 15mg QD (29.8 vs. 16.6%;
SD" 0.32) and apixaban 2.5mg BID (28.6 vs. 20.2%; SD" 0.20). Small differences were
observed for dabigatran 110mg (47.2 vs. 40.7%; SD" 0.13). These findings can be
explained by a more frequent use of the lower NOACs doses in >75years Italian
patients. Proton pump inhibitors (PPI) for gastric protection were more often chosen in
Italy than in OWE (43.0 vs. 29.0%; SD" 0.30) independently of age and OAC.
Conclusions: GLORIA-AF Phase III results show the existence of relevant differences
in OAC use between Italy and other Western European Countries. Older Italian NOACs
users more often receive the lower dosages of the drugs. The prevalence of those
not taking anticoagulants is still high, highlighting the importance of a better AF
management in routine clinical practice.
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Introduction: Despite the evolution of transvenous implantable cardioverter defibril-
lator (ICD) during the last 30 years, associated short- and long-term risks (e.g. surgi-
cal complications, lead malfunctions and infections) remain unacceptably high. In
the attempt to overcome such limitations, subcutaneous implantable cardioverter
defibrillator (s-ICD) became available for clinical use since 2009 providing a valuable
alternative to transvenous ICDs in patients without pacing needs.
Aim of the Study: To study the efficacy and safety of s-ICD in real world cohort of
patients consecutively implanted at a single high-volume Institution.
Results: 62 patients (female" 8, 12.9%) underwent s-ICDs implantation between 2014
and 2019. Mean age at implant was 53 yrs (614yrs) and primary prevention of SCD was
the main indication (40 patients, 64.5%). Underlying aetiology of cardiac disease was
mostly ischaemic (27 patients, 43.5%) followed by non-ischaemic cardiomyopathy (17
patients, 27.4%). Patients with channelopathies and genetic cardiac disease were
implanted less frequently (e.g. Brugada syndrome in 7 [11.3%] patients, hypertrophic
cardiomyopathy in 3 [4.8%] patients) Idiopathic ventricular fibrillation was the indica-
tion to s-ICD implantation in 4 patients (6.5%). In 6 patients, a permanent transvenous
device was already in place and required extraction and replacement with a s-ICD for
infective causes in 4 cases (6.4%). Mean left ventricular ejection fraction (LVEF) at the
time of implant was moderately reduced (LVEF" 38615%). Background medical therapy
was overall well balanced (beta-blockers, ACE-I/ARB, MRA used respectively in 80.9%,
67.7% and 53.2% of patients). During defibrillation threshold test, sinus rhythm was suc-
cessfully restored after first shock in all but three cases in which the opposite polarity
defibrillation was used. Overall, mean time to sinus rhythm restoration was 16 seconds
(64 seconds). In two patients (3.2%) induction test was not performed based on clinical
decision (i.e. intraventricular thrombus, recent ab-ingestis pneumonia), while in 9
(14.5%) patients the standard protocol did not induce sustained arrhythmias. At median
follow-up of 12months [25#-75# IQR, 3months-27months], 8 (9.6%) patients received
an appropriate shock (6 for sustained VT, 2 for VF) with 100% restoration of sinus
rhythm after single shock whereas 3 (4.8%) patients underwent inappropriate shocks
(two caused by myopotentials oversensing). During follow-up, two patients died (one
for cardiovascular cause – pump failure), while 19 were admitted for cardiovascular
causes (mainly for hearth failure decompensation). Only 4 patients (6.4%) suffered from
minor complications linked to s-ICD implant: one subxiphoid keloid (surgically treated),
one iatrogenic lead damage during cardiac surgery (requiring new lead implantation),
one lead dislodgement (surgically treated) and one mild hematoma (treated conserva-
tively). Duration of s-ICD implantation became significantly shorter with time (mean
procedural time during the first three years " 102minutes vs. mean procedural time
during the second three years " 82minutes) and preference for inframuscular instead
of subcutaneous implantation was observed.
Conclusions: Based on our experience, the use of s-ICD for SCD prevention (both in
primary and secondary setting) is effective, with very low complication rates at
medium term follow-up. The implantation learning curve is relatively steep: short
procedural times, minimal surgical incisions, excellent cosmetic results are achiev-
able after a limited number of procedures.
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Introduction: The benefits of cardiac resynchronization therapy with defibrillator
(CRT-D) in heart failure are well established. However, a gap of evidence is still
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